Mattina R, Cocuzza C E, Cesana M, Bonfiglio G
Institute of Medical Microbiology, University of Milan, Italy.
Chemotherapy. 1991;37(4):260-9. doi: 10.1159/000238865.
The in vitro activity of rufloxacin (MF 934), a new broad-spectrum fluoroquinolone, was tested against 1,032 gram-positive and gram-negative clinical isolates and compared to that of five other compounds of this class. All quinolones except for ciprofloxacin had limited activity against group A and B streptococci and pneumococci (MIC 90% of 4-64 mg/l) and no activity against enterococci. Most species of the enterobacteriaceae and staphylococci were found to be sensitive to rufloxacin (MIC 90% of 0.5-8 and 2-8 mg/l). Like the other quinolones except for ciprofloxacin, rufloxacin was not active against Pseudomonas aeruginosa. The antibacterial activity of rufloxacin was affected only minimally by an increase in the bacterial inoculum or by alterations in the pH of the medium. In spite of the relatively higher MICs of rufloxacin compared to those of the other quinolones, its favorable pharmacokinetic properties may account for its good clinical efficacy.
新型广谱氟喹诺酮类药物鲁氟沙星（MF 934）的体外活性针对1032株革兰氏阳性和革兰氏阴性临床分离菌株进行了测试，并与该类别的其他五种化合物进行了比较。除环丙沙星外，所有喹诺酮类药物对A组和B组链球菌及肺炎球菌的活性有限（MIC 90%为4 - 64毫克/升），对肠球菌无活性。发现大多数肠杆菌科和葡萄球菌对鲁氟沙星敏感（MIC 90%为0.5 - 8和2 - 8毫克/升）。与除环丙沙星外的其他喹诺酮类药物一样，鲁氟沙星对铜绿假单胞菌无活性。细菌接种量增加或培养基pH值改变对鲁氟沙星的抗菌活性影响极小。尽管鲁氟沙星的MIC相对高于其他喹诺酮类药物，但其良好的药代动力学特性可能解释了其良好的临床疗效。
